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Background—Studies have suggested that the prevalence of antibodies against heat-shock proteins (HSPs), Chlamydia
pneumoniae (Cpn), and cytomegalovirus (CMV) is associated with coronary artery disease (CAD), but the independent
or joint effects of human (h) HSP60 antibodies and these pathogens in patients have not been fully elucidated.
Methods and Results—A total of 405 subjects (276 patients with CAD and 129 control individuals) were tested for serum
antibodies to hHSP60, Cpn, and CMV immediate-early-1 (IE1) antigens. Patients were also assessed for serum
cholesterol, triglyceride levels, and smoking habit. Significantly elevated levels of antibodies to hHSP60 and Cpn but
not to CMV-IE1 antigens were documented in CAD patients. Multiple logistic regression analysis and subanalyses of
selected subjects showed that these associations were independent of age, sex, smoking, and serum lipid levels.
Antibodies to hHSP60 and Cpn did not correlate quantitatively; however, the relative risk of disease development was
substantially increased in subjects with high antibody levels to both hHSP60 and Cpn, reaching an odds ratio of 82.0
(95% CI 10.6 to 625.0).
Conclusions—High levels of antibodies to hHSP60 and Cpn are independent risk factors for coronary atherosclerosis, but
their simultaneous presence substantially increases the risk for disease development. (Circulation. 2001;103:1503-
1508.)
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The role of infectious agents in the pathogenesis ofatherosclerosis has long been suggested. The pathogens
implicated in the development of an inflammatory reaction,
the first step in the disease process, include Chlamydia
pneumoniae (Cpn) and cytomegalovirus (CMV).1,2 An auto-
immune component of atherosclerotic disease has also been
proposed, and heat-shock protein 60 (HSP60) has been
reported as a putative autoimmune antigen.3
From 50% to 80% of adults worldwide have antibodies to
Cpn, a common respiratory pathogen. Cpn replicates intra-
cellularly and expresses various proteins, including the major
outer membrane protein (MOMP) and chlamydial HSP60.
Chronic infection with Cpn is common.4
CMV is among the infectious agents that usually cause no
symptoms in immunocompetent individuals but do establish
latent infection. From 50% to ’100% of adults are seropositive.
The immediate-early (IE) proteins of CMV influence transcrip-
tion from cellular and viral promoters, are involved in escape
from immune surveillance and in establishment of virus latency,
and are the first proteins expressed after virus reactivation.5
Numerous studies have reported increased Cpn antibody
levels in atherosclerotic patients, although several prospective
studies found no significant correlation between the presence of
Cpn antibodies and incidence of myocardial infarction.6 The
seroepidemiology of CMV infections in atherosclerotic and
control individuals is even less clear, with results suggesting
elevated CMV antibody levels in patients with primary athero-
sclerosis7 or with restenosis after angioplastic surgery,8 or no
association.9 Human CMV-IE antigens have been implicated in
the restenosis process, because IE proteins are locally reactivated
in the coronary walls, and the IE2 protein binds to and sup-
presses the function of tumor-suppressor p53 in the infected
vessel wall.10 No studies to date have included measurement of
CMV-IE antibodies in seroepidemiological analyses of athero-
sclerosis or restenosis development.
Significantly increased levels of serum antibodies to
HSP65 have been reported in patients with coronary and
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carotid atherosclerosis.11–13 Some bacteria contain HSPs, and
some viruses induce overproduction of human (h) HSP60 by
the infected cell, leading to immunogenicity of the protein
due to structural alterations or posttranslational modifica-
tions.14 Thus, antigenic mimicry by HSPs may be the link
between infections and atherosclerosis.
Most seroepidemiological studies have focused on mea-
surement of antibodies against a single pathogen or against
HSPs. A few studies have assessed antibodies to multiple
pathogens, including CMV and Cpn,15–17 or to Cpn and
HSPs18 in the same individuals. In the present study, we
measured antibody levels against Cpn, CMV-IE1, and
hHSP60 in the same case/control population to further exam-
ine the potential combined effects of these factors in the
development of atherosclerotic disease.
Methods
Study Population
The study population of 405 subjects (aged 35 to 77 years) was
divided into 4 groups. Group 1 consisted of 248 patients with severe
coronary artery disease (CAD) who underwent coronary angiogra-
phy19 in 1995 to 1996 at the National Institute of Cardiology,
Budapest, Hungary, with significant stenosis (.50% occlusion),
clinical signs of stable or unstable angina pectoris, and typical ECG
abnormalities. Group 2 comprised 28 patients with mild CAD who
underwent angiography at the same institute, with nonsignificant
stenosis (,50% occlusion), clinical signs of stable or unstable
angina pectoris, and typical ECG abnormalities. Group 3 comprised
53 control patients with clinical symptoms of stable angina pectoris
and no coronary alterations detected on angiography. Finally, group
4 was composed of 76 blood donors who were apparently healthy on
physical examination and were without history of CAD. All patients
in group 1 received aortocoronary bypass graft by open heart
surgery. Patients in groups 1, 2, and 3 received either antihyperten-
sive therapy (when systolic/diastolic blood pressure measured in
sitting position was .140/90 mm Hg) or lipid-lowering therapy
(when serum total cholesterol or triglycerides exceeded 5.6 mmol/L
or 2.2 mmol/L, respectively). In some analyses, data from group 1
(severe CAD) and group 2 (mild CAD) were combined (combined
group A), and data from group 3 (patient controls) and group 4
(blood donors) were combined (group B). Smoking habit of patients
in groups 1, 2, and 3 was recorded. The project was approved by the
Ethics Committee of the Semmelweis University, Budapest, Hun-
gary; informed consent forms were signed by the patients.
Cpn Antibodies
Sera were tested at a 1:128 dilution for Chlamydia-specific IgG
antibodies with a microimmunofluorescence assay (ServiMif Chla-
mydia, SERVIBIO), according to the manufacturer’s instructions.
Sera were designated as positive (titer $1:128) or negative (titer
,1:128) based on typical fluorescence associated with evenly
distributed Chlamydia organisms. Sera positive for Chlamydia tra-
chomatis or Chlamydia psittaci antigens were excluded from the
study.
CMV-IE1 Antibodies
Serum IgG antibodies to CMV-IE1 antigen were determined by
in-house–developed ELISA. For antigen production, chicken em-
bryo fibroblasts were infected with a recombinant canarypox virus
expressing CMV-IE exon4 protein.20 Parental canarypox virus–
infected cell lysate served as control antigen. Serum samples were
tested in dilution of 1:100 in a standard ELISA. Optical density (OD)
values measured on parental canarypox antigen were subtracted from
OD values on canarypox CMV-IE exon4 antigen. Antibody levels
were considered “low” at a calculated OD ,1.00 and “high” at
OD$1.00.
hHSP60 Antibodies
IgG reacting with recombinant hHSP60 (SPP-740, StressGen) was
quantified by ELISA at a serum dilution of 1:500 as described
previously.21 Serial dilutions of a control anti-hHSP60 rabbit poly-
clonal antiserum (StressGen SPA-840) were used as standard. OD
values were calculated in arbitrary units per milliliter relative to the
standard.
Clinical Laboratory Procedures
Serum cholesterol and triglyceride were measured PAP (peroxidase-
anti-peroxidase) by enzymatic colorimetric assay using enzachol-F
and ENZGlycid reagents (Diachem). LDL cholesterol was calculated
according to the Friedewald formula.22 The level of lipoprotein(a)
[Lp(a)] was determined by ELISA.23
Statistical Analyses
All statistical analyses were performed with SPSS for Windows
program version 9.0. Differences between groups in continuous
variables were estimated with independent-sample t test, nonpara-
metric Mann-Whitney U test, or Kruskal-Wallis test. For dichoto-
TABLE 1. Clinical Characterization and Risk Factors in Patients With Severe and Mild CAD
and Control Subjects
Patients (Combined
Group A) (n5276)
Controls (Combined
Group B) (n5129) P
Age, y
Mean 58.7 56.3 0.042*
Range 35–77 35–77
Male sex, % 77.2 62.8 0.004*
High level of anti-CMV-IE1†, % 35.5 31.0 0.431
Anti-hHSP60, U/mL
Median 102.2 49.0 ,0.0001*
Range 0–2410 0–722
High (.160 U/mL) level of anti-hHSP60‡, % 31.5 3.9 ,0.0001*
Cpn-positive§, % 79.3 60.5 0.0001*
*Significant difference.
†OD .1.0 at serum dilution 1:100.
‡Highest quartile.
§Titer $1:128.
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mous variables, x2 test or Fisher’s exact test was used. ORs and 95%
CIs were calculated. All tests were 2-tailed. Logistic regression was
used to evaluate potential confounding by covariables and to
calculate adjusted ORs. To assess the effect of high hHSP60
antibody levels on CAD development, dichotomous variables were
created for hHSP60 antibody levels, ie, high (highest quartile) versus
low (lower 3 quartiles of the distribution). This approach was
selected because of skewed distributions of hHSP60 antibodies and
because the risk associated with hHSP60 antibodies did not differ in
the lower quartiles of distribution. Sets of 4 binary indicators were
created for each interaction investigated. In the joint-effect analyses,
subjects with low levels of both antibodies of interest were used as
reference to estimate the relative risk of the other 3 combinations.
Differences were considered significant at P,0.05.
Results
Demographic Characterization and Risk Factors
in Patients With Severe/Mild CAD Versus Control
Patients/Blood Donors
Table 1 summarizes the demographic data and the CMV-IE1,
hHSP60, and Cpn antibody levels in the sera of patients with
severe and mild CAD (combined group A) versus patient
controls and blood donors (combined group B). Because of a
slight dissimilarity in age distribution, a difference of border-
line significance in the mean age of the 2 groups was seen.
The percentage of males was significantly different. There
was no significant difference between CMV-IE1 antibody
levels (high or low) in the 2 groups. The most striking
differences were found in (1) hHSP60 antibody levels,
calculated as either median and range of units (continuous
variables) or as percentage of individuals with high levels
(highest quartile) of anti-hHSP60, and (2) Cpn seropositivity
(titer $1:128) (Table 1). Logistic regression analysis of
hHSP60 antibody levels (high and low) adjusted for sex and
age confirmed a significantly higher percentage of subjects
with high hHSP60 antibody levels in combined group A than
in combined group B (P50.0004; OR 5.4; 95% CI 2.1 to
14.0).
Sera of subjects in the clinically more homogeneous
groups 1 and 3 were also compared for total serum choles-
terol, HDL, LDL, triglyceride, and Lp(a) levels, and smoking
habit was recorded. Table 2 summarizes the results of these
measurements, as well as levels of hHSP60, Cpn, and
CMV-IE1 antibodies. Age, sex, and total and LDL cholester-
ol levels, as well as CMV-IE1 antibody levels, were similar in
both groups. HDL cholesterol was lower and triglyceride and
Lp(a) levels were higher in group 1 than in group 3. There
was a borderline significant difference in the percentage of
smokers. Antibody levels to hHSP60 and Cpn remained
significantly higher in group 1 than in group 3 (Table 2).
When data were adjusted for age, sex, smoking habits, and
HDL cholesterol, triglyceride, and Lp(a) levels by logistic
regression analysis, anti-hHSP60 levels (high or low,
P50.0037, OR 9.8, 95% CI 2.1 to 45.9) and the percentage of
Cpn seropositives (P50.047, OR 2.4, 95% CI 1.01 to 5.72)
were significantly higher in group 1 than group 3. The same
parameters were also compared in 35 patients (group 1) and
35 controls (group 3) selected on the basis of same age 64.5
years, same sex, and similar cholesterol values; CMV-IE1
antibody levels were not significantly different, whereas
statistically significant differences were seen for Cpn sero-
positivity (P50.009, OR 4.6, 95% CI 1.5 to 14.7) and for
hHSP60 antibodies (high or low: P50.012, OR 3.4, 95% CI
1.0 to 12.5). Furthermore, in group 1, there were 40, 28, and
189 patients undergoing treatment with statin, fibrate, and
aspirin, respectively, at the time of blood sampling. No
differences in the percentage of Cpn seropositives or serum
concentrations of hHSP60 antibodies were found between
patients with or without treatment (not shown).
Lack of Correlation of Cpn Seropositivity With
hHSP60 Antibody Levels; Correlation With
Smoking Habit
Comparison of hHSP60 antibody levels (continuous variable)
in Cpn-negative and Cpn-positive individuals revealed no
statistical difference between the 2 groups in the total study
population, in either CAD group, or in either control group
(Table 3). Moreover, in either CAD group, no statistical
difference was seen between Cpn seropositives and seronega-
tives in the percentage of subjects with high-level (highest
TABLE 2. Clinical Characterization and Risk Factors in Patients With
Severe CAD (Group 1) Versus Control Patients (Group 3)
Patients With
Severe CAD
(n5248)
Control Patients
(n553) P
Age, y
Mean 58 60
Range 35–76 38–74 0.184
Male sex, % 76.6 67.9 0.220
Smokers, % 81.1 68.4 0.074
Total cholesterol, mmol/L
Median 6.20 6.20
Range 3.40–20.00 4.00–10.1 0.409
HDL cholesterol, mmol/L
Median 1.27 1.30
Range 0.67–2.05 1.14–1.37 0.0063*
Triglycerides, mmol/L
Median 2.00 1.60
Range 0.3–16.6 0.90–6.30 0.016*
LDL cholesterol, mmol/L
Median 3.96 4.00
Range 0.77–8.09 0.80–8.00 0.867
Lp(a), mg/dL
Median 16.23 6.08
Range 0.01–136.2 0.01–168.1 0.0002*
High level of anti-CMV-IE1†, % 33.8 32.0 1.00
Anti-hHSP60, U/mL
Median 101.9 56.6
Range 0.0–2410.0 0.0–722.1 0.0001*
High (.180 U/mL)
level of anti-hHSP60‡, %
29.4 5.7 0.0001*
Cpn-positive§, % 79.4 64.2 0.021*
*Significant difference.
†OD .1.0 at serum dilution of 1:100.
‡Highest quartile.
§Titer $1:128.
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quartile) hHSP60 antibodies (P50.260 to 0.869) (not shown).
By logistic regression analysis of data for Cpn seropositivity
adjusted for sex, age, and hHSP60 antibodies (continuous
variable), the probability value remained significant in all
combinations of case and control groups, and ORs varied
between 2.2 and 2.6 (Table 4). No correlation between
hHSP60 and HCMV-IE1 antibodies was observed (not
shown).
In groups 1, 2, and 3, Cpn seropositivity was significantly
associated with smoking; 81.1% of smokers but only 68.4%
of nonsmokers tested positive for Cpn antibodies (P50.018).
Joint Effects of Microbial and hHSP60 Antibodies
in the Development of Atherosclerosis
The simultaneous occurrence of high hHSP60 and high
microbial antibodies was analyzed in combined group A
versus combined group B with respect to the relative risk of
CAD (Table 5). In subjects with Cpn antibody titers $1:128
and with high hHSP60 antibody levels (highest quartile), the
risk of CAD was dramatically increased relative to subjects
with no or low levels of Cpn antibodies and low levels of
hHSP60 antibodies (lower 3 quartiles) (nonadjusted OR 83.3;
adjusted for age and sex, OR 82.0) (Table 5). ORs for
subjects with high hHSP60 antibodies and Cpn seropositivity
(titer $1:128) in group 1 were also high compared with group
3 (adjusted for age and sex, P50.0007, OR 38.3, 95% CI 4.7
to 312.5) (not shown). However, the simultaneous presence
of high CMV-IE1 and high hHSP60 antibody levels was not
associated with increased risk. The simultaneous presence of
high levels of CMV-IE1 and Cpn antibodies did not change
the ORs (Table 5).
Discussion
In our study, elevated Cpn and hHSP60 antibodies but not
CMV-IE1 antibodies were significantly associated with a
population of angiographically confirmed severe and moder-
ate CAD patients versus patient controls and blood donors
and with a population of severe CAD patients versus patient
controls. Antibodies to hHSP60 and Cpn were present inde-
pendently in the study population, but a potent joint effect of
high levels of hHSP60 and Cpn antibodies was observed,
indicating that the coincidence of Cpn infection and high
level of autoantibodies to hHSP60 is a strong risk factor for
CAD development.
Cpn antibodies have been shown to be associated with
increasing age, male sex, and smoking.6 In the present study,
the Cpn antibody data were adjusted for age, sex, serum lipids
[including Lp(a)], and smoking by logistic regression, and
statistically significant differences and ORs suggest a 2- to
3-fold higher risk for CAD in individuals with elevated Cpn
antibodies.
Our analysis of high and low Cpn-specific antibody titers
did not distinguish between subjects with low titers (,1:128)
and those never infected but rather may distinguish subjects
with frequent, recent, or chronic infections from those with
less frequent, less recent, or milder infections. However,
misclassification of prior infection based on current high
antibody status ($1:128) was probably equal in the case and
control groups. Also, blood donors were not examined by
angiography, so that some individuals with asymptomatic
CAD may have been incorrectly classified as controls.
However, such misclassification would be reflected in a
lower OR, making the reported OR a conservative estimate.
Bacterial and viral infections can induce immune reactivity
against hHSP60, which may serve as a target for autoimmune
reactions. Our results for elevated levels of hHSP60 in CAD
patients are in agreement with previous observations for
HSP65.11,12 Our study revealed no quantitative correlation
between hHSP60 and Cpn antibodies as detected by a
microimmunofluorescence assay that is most likely specific
for MOMP,24 and the data suggest that hHSP60 and Cpn are
independent risk factors in the development of the disease.
Circulating hHSP60 antibodies might be maintained at higher
levels through different mechanisms (for example, through
infection with agents containing homologous HSPs). Other
mechanisms, such as hypertension25 or oxidized LDL,26
TABLE 4. Logistic Regression Analysis of Cpn Seropositivity* Adjusted for Sex, Age,
and Anti-hHSP60†
Groups
No. of Cases/Controls
Seropositive for Cpn P OR (95% CI)
Patients with severe/moderate CAD (combined group A)
vs control patients/blood donors (combined group B)
276/129 0.0010‡ 2.4 (1.4–4.0)
Patients with severe CAD (group 1) vs patient controls
(group 3)
248/53 0.025‡ 2.2 (1.1–4.3)
Patients with severe CAD (group 1) vs blood donors
(group 4)
248/76 0.0056‡ 2.6 (1.3–5.0)
*Titer $1:128.
†Adjusted for continuous variables of anti-hHSP60 units.
‡Significant difference.
TABLE 3. Lack of Correlation Between hHSP60 Antibody
Levels and Cpn Seropositivity
Groups
Anti-hHSP60, Median (Range) (n), U/mL
PCpn Negative* Cpn Positive†
Total study population 73 (0–2410) (108) 83 (0–805) (296) 0.740
Severe CAD 102 (1–2410) (51) 100 (0–805) (197) 0.321
Moderate CAD 110 (43–207) (6) 99 (25–293) (21) 0.705
Patent controls 50 (0–722) (19) 72 (0–177) (34) 0.711
Blood donors 53 (13–213) (32) 44 (0–143) (44) 0.415
*Titer #1:128.
†Titer $1:128.
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might also stimulate HSP60/70 expression and, in turn,
increased HSP60/70 antibody levels. The independent pres-
ence of hHSP60 and Cpn antibodies suggests that hHSP60
antibodies are predominantly induced by mechanisms other
than Cpn infection. Alternatively, high levels of autoantibod-
ies against hHSP60 may be a stable, genetically determined
trait (Amarilla Veres, MD, and Tamas Szamosi, MD, unpub-
lished observations, 2000) that predisposes to CAD by
formation of abundant hHSP60–anti-hHSP60 immune com-
plexes21 and may result in intense in situ complement
activation and endothelial cell dysfunction.
A previous study18 concluded that high-titer antibodies to
mycobacterial HSP65 correlated with the presence of anti-
bodies to Cpn in human sera obtained from atherosclerotic
patients and that the HSP65 antibodies cross-reacted with
hHSP60, chlamydial HSP, and Escherichia coli Gro-EL in
ELISA. Our results contrast with this observation, possibly
owing to differences in the study populations used, the
evaluation of high or low levels of antibodies to Cpn, or the
type of HSP antibodies investigated (antibodies to mycobac-
terial HSP65 or hHSP60). However, a recent report27 that
CAD patients were more likely to have IgG antibodies to Cpn
than were individuals without CAD but that CAD was not
associated with antibody response to chlamydial HSP60
supports our observation. Furthermore, marked differences in
the complement-activating ability and epitope specificity
were found between HSP65 and hHSP60 antibodies present
in CAD patients.21
We found no significant difference in the percentage of
individuals with high anti-CMV-IE1 levels in patients versus
controls. A problem throughout seroepidemiological studies
of CMV is the high infection rate of the population world-
wide (50% to ’100%).5 Based on the detection of antibodies
to whole CMV, ’90% of the adult Hungarian population is
seropositive (K. Burian, MD, unpublished observation,
1999). Thus, these results do not exclude the possibility of the
involvement of CMV in the development of some forms of
CAD.
Previous analyses of the simultaneous presence of elevated
Cpn and CMV antibodies to whole virion in the same
populations suggested an association between Cpn infection,
but not CMV infection, and CAD.15,17 Our findings are in
accord with those data on elevated Cpn seropositivity in
patients with CAD, and the results obtained by detection of
CMV-IE1 antibodies are also consistent with those findings.
We found that the simultaneous presence of hHSP60
antibodies and Cpn antibodies is associated with a striking
increase in the risk (OR 38.3 to 82.0) for development of
CAD. On the other hand, no joint effects of the simultaneous
presence of high hHSP60 and high CMV-IE1 antibodies were
revealed, indicating differences between microbial infections
in the interaction with hHSP antibodies.
In patients with CAD, a potent joint effect has also been
described for the simultaneous presence of C-reactive protein,
an acute phase protein used as a marker for inflammation, and
antibodies to herpes simplex virus 1 (HSV-1); the OR in
subjects with high HSV-1 antibody and high C-reactive
protein levels was 25.4 (95% CI 2.9 to 220.3).17 That finding,
together with our results, supports the hypothesis that inflam-
matory reactions, infections with certain pathogens, and
hHSP60 induced by various stimuli in endothelial or other
cells act independently, but their simultaneous presence
greatly increases the risk for disease development.
In summary, our present data indicate the independent
presence of elevated Cpn and hHSP60 antibodies in CAD
patients and the substantially increased OR for CAD in
individuals with the simultaneous presence of Cpn antibodies
at titers $1:128 and high levels of hHSP60 antibodies. These
results might provide direction in further studies on the
mechanisms underlying coronary artery diseases.
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